ImmunoGen News

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

ImmunoGen, Inc . , a biotechnology company that develops targeted anticancer products, announced today the appointment of Suzanne Cadden as Vice President of Regulatory Affairs & Quality.

Shares of the following companies may have unusual moves in U.S. trading today. Stock symbols are in parentheses, and prices are as of 7:48 a.m. in New York.

An eye-opening overall response rate of 32.7 percent in Phase II trials with antibody-drug conjugate TDM-1 in last-resort breast cancer patients left investors in ImmunoGen Inc.

ImmunoGen is expected to announce Monday a commitment by its partner Roche to begin new late-stage clinical trials of the experimental breast cancer drug T-DM1. The overall goal of this new clinical trial program will be to determine whether T-DM1, which is still not approved for use, can one day replace Roche's Herceptin as the leading treatment ...

A a oeguided missilea combination drug called T-DM1 developed by Roche Holding AG and Immunogen Inc.

T-DM1 comprises ImmunoGen's DM1 cancer-cell killing agent linked to the HER2-targeting antibody, trastuzumab, developed by Genentech, a wholly owned member of the Roche Group.

Immunogen Inc. said Wednesday its developing cancer treatment T-DM1 prompted a 32.7 percent response rate in a midstage study on breast cancer patients, pushing shares higher.

ImmunoGen just disclosed partial results from the pivotal study of T-DM1 in third-line breast cancer patients that's to be presented at a medical meeting on Saturday.

ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology 51st Annual Meeting and Exposition.

ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma , including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

SUNNYVALE, Calif.-- --Harmonic Inc. today announced that Patrick Harshman, President and Chief Executive Officer, and Robin Dickson, Chief Financial Officer, will make a p... WALTHAM, Mass.-- --ImmunoGen, Inc.

The month of December has always been a busy period for biotech investors, due to two important events: The annual meeting of American Society of Hematology and the San Antonio Breast Cancer Symposium .

Happy Black Friday! The Biotech Stock Mailbag comes to you today 50% off due to the holidays.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload technology will be made at the 51st American Society of Hematology Annual Meeting and Exposition to be held in New Orleans, LA, on ...

Drugmaker ImmunoGen Inc said it licensed its technology to develop anti-cancer drugs to Amgen Inc for a $1 million upfront payment.

Waltham biotechnology firm ImmunoGen Inc. has announced a second license granted to Amgen Inc.

ImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second potential cancer-treatment from the company for $1 million upfront.